THDG3
THDG3:
A neuroprotectant with potential uses in a range of hypoxic-ischemic brain injuries THDG3 was developed at Columbia University and is the cornerstone of DeckTherapeutics’ pipeline
Indications
Neonatal hypoxic-ischemic encephalopathy (HIE)
Insufficient supply of oxygen during labor and/or delivery causes brain injury in tens of thousands of newborns every year. HIE is the most common cause of cerebral palsy in full-term infants
Indications
Ischemic stroke is the 5th most common cause of death in the US
Ischemic stroke is one of the largest and most costly unmet medical needs. Tissue plasminogen activator (t-PA) and thrombectomy can be used to restore blood flow in some patients but no neuroprotectant is approved to date
Partnering
DeckTherapeutics seeks to partner its omega-3 platform
Contact us to discuss how we together can leverage DeckTherapeutics’ world class expertise and IP in the area of acute omega-3 therapeutics
News
August 3, 2021
DeckTherapeutics announces grant of patent
The US Patent and Trademark Office today issued the patent US 11,076,593 claiming inventions relating to “Reperfusion with omega-3 glycerides promotes donor organ protection for transplantation”. The inventors include DeckTherapeutics’ scientific founder and Chair of the Scientific Advisory Board Dr. Richard Deckelbaum and DeckTherapeutics has an option to obtain an exclusive license to this and other patents from Columbia University.
January 7 2021
DeckTherapeutics announces the formation of Scientific Advisory Board
DeckTherapeutics today announced the formation of a Scientific Advisory Board comprised of some of the world’s foremost clinician scientists, practitioners and clinical trial experts, in the area of treating hypoxic-ischemic brain injuries.
January 1 2021
DeckTherapeutics participates in Biotech Showcase
Reach out to discuss investing or partnering during the conference January 11-13, 2021.
The annual partnering and investor conference Biotech Showcase is fully virtual in 2021 but the team at DeckTherapeutics is looking forward to meeting remotely with life science investors and people from the industry during this busy week.
Please reach out if you are interested in learning more.
December 11, 2020
DeckTherapeutics appoints new CEO
The biotech entrepreneur Soren Weis Dahl, PhD, MBA today succeeded Suman Lal, MD, PhD, MBA as chief executive of DeckTherapeutics. Dr. Dahl successfully led the development and sale to Rallybio of two orphan drug assets (press release) and will oversee the development of THDG3 in the rare neonatal condition of HIE. Dr. Lal was instrumental in building DeckTherapeutics and the team after the spin-out from Columbia University and will continue to be part of the management team in his new role as Chief Operating Officer.
December 1, 2020
DeckTherapeutics obtains exclusive license to omega-3 IPR from DSM Nutrition
DeckTherapeutics today announced that the company has signed a letter of intent towards a exclusive intellectual property licensing agreements with the DSM Nutrition. The agreement provides access for DeckTherapeutics to use a proprietary process for manufacturing of novel semi-synthetic omega-3 glycerides towards development of novel intravenous omega-3 fatty acid emulsions
March 30, 2020
DeckTherapeutics obtains exclusive license to omega-3 IPR from the United States Army
DeckTherapeutics today announced that the company has entered into an exclusive intellectual property licensing agreement with the United States Army on the use of certain intravenous omega-3 fatty acid emulsions in treatments of acute brain injuries